Heart Failure

Researchers at Tel Aviv University in Israel have 3D-printed what they said is the first vascularized heart using a patient’s own cells and biological materials.

An April 2 story in the New York Times highlighted a potentially dangerous insurance coverage gap faced by heart transplant patients and recipients of other organs—the immunosuppressive drugs they need to prevent organ rejection sometimes aren’t covered by Medicare if they received the transplants before enrolling in the program.

A team-based protocol for treating cardiogenic shock helped one center boost its 30-day survival rates for those patients by nearly 20 percentage points over a two-year period, researchers reported in the Journal of the American College of Cardiology.

A study of nearly 900,000 patients with heart failure or cardiogenic shock revealed their race, insurance coverage and ZIP code were associated with their odds of receiving a left ventricular assist device (LVAD).

Nearly a quarter of heart failure patients discharged after rehabbing in skilled-nursing facilities (SNFs) are bound to get readmitted to hospitals within 30 days of going home. And those whose stay at the SNF two days or fewer are up to four times more likely to be readmitted than those who stay longer.

Compared to warfarin, all direct oral anticoagulants (DOACs) were associated with fewer cardiovascular events including heart attacks and strokes in a study of Medicare patients with both nonvalvular atrial fibrillation and heart failure. But apixaban appeared to offer the best balance of protecting against these events while minimizing bleeding risk.

In the latest study to link influenza and cardiovascular disease, researchers found that the most severe flu seasons coincided with spikes in hospitalizations for heart failure.

A new report from Australia highlighted the feasibility of transplanting hearts from donors who have experienced circulatory death—a practice which, if adopted, could expand heart transplant volume by an estimated 20 percent.

The FDA has approved the Optimizer Smart system as an implantable treatment option for heart failure patients with left ventricular ejection fraction between 25 and 45 percent who aren’t candidates for cardiac resynchronization therapy (CRT).

Researchers from the Rochester Institute of Technology are leveraging “natural processes” to provide insights into heart health with a toilet seat-based cardiovascular monitoring system.

A post-FDA approval study of Abbott’s CardioMEMS heart failure sensor found the device reduced HF-related hospitalizations by 58 percent in a trial group of 1,200 patients, researchers reported at this year’s American College of Cardiology symposium in New Orleans.

A remote monitoring protocol for heart failure patients with implantable electronic devices helped more of them stay out of the hospital over a one-year period than standard in-person visits, researchers reported at EHRA 2019.